GW Pharmaceuticals reports that Sativex has received regulatory approval in Austria as a treatment of spasticity due to Multiple Sclerosis (MS). The launch of Sativex in Austria is expected to take place during 2012 following completion of the national pricing and reimbursement process.
Leave a Reply
You must be logged in to post a comment.